Abstracts tagged "Scleroderma"

Abstract Number: 1378 • ACR Convergence 2021
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
Matthew Kirkpatrick¹, Janet Lee¹, Anne Tebo², Haojia Li¹, yue zhang¹ and Tracy Frech¹, ¹University of Utah, Salt Lake City, UT, ²Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important…
Abstract Number: 0395 • ACR Convergence 2021
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Megan Lockwood¹, Yuqing Zhang², Marcy Bolster¹, Sara Schoenfeld¹, Xiaoqing Fu¹, Seth Brownmiller¹, Ana Fernandes¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
Abstract Number: 1380 • ACR Convergence 2021
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
Aditi Patel¹, Mehnaj Grewal², Robert Butler² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Calcinosis cutis (CC) can commonly affect patients with systemic sclerosis (SSc), which is often painful, resulting in functional impairment and morbidity. A radiographic scoring…
Abstract Number: 0405 • ACR Convergence 2021
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Hao Cheng Shen¹, Catherine Faucher², Anne Chin³, Carl Chartrand-Lefebvre³, Ragui Chehata⁴, Julia Cadrin-Tourigny⁵, Francois-Pierre Mongeon⁶, Jean-Paul Makhzoum⁷, Océane Landon-Cardinal⁸, Josiane Bourré-Tessier⁸, Éric Rich⁹, Jean-Richard Goulet⁸, Paul R Fortin¹⁰, Jean-Luc Senécal⁸ and Sabrina Hoa⁸, ¹Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Department of Medicine, Université Laval, Québec, QC, Canada, ³Department of Radiology, Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Université de Montréal, Montreal, Montréal, QC, Canada, ⁵Division of Non-Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Division of electrophysiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁷Division of Internal Medicine, Hôpital Sacré-Coeur de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁸Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Centre hospitalier de l’Université de Québec-Université Laval, Montréal, QC, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Cardiac involvement is a leading cause of death in systemic sclerosis (SSc). Cardiac MRI (CMR) is useful in the early assessment of cardiac disease.…
Abstract Number: 1381 • ACR Convergence 2021
Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
Imon Barua¹, Håvard Fretheim², Hilde Jenssen Bjørkekjær³, Henriette Didriksen⁴, Oyvind Midtvedt², Trond Mogens AAløkken², Torhild Garen⁵, Oyvind Molberg⁶, John Belperio⁷ and Anna-Maria Hoffmann-Vold¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, ⁴Oslo University Hospital, Moss, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, ⁶Oslo University Hospital, Oslo, Nepal, ⁷University of California Los Angeles Interstitial Lung Disease Center, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…
Abstract Number: 0412 • ACR Convergence 2021
Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Ashima Makol¹, Caitrin Coffey¹, Tina Gunderson¹, Alicia Hinze¹, Yasser Radwan², Cynthia Crowson³, David Liedl¹, Kenneth Warrington¹ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, ²Michigan State University, Lansing, MI, ³Mayo Clinic, Eyota, MN
Background/Purpose: To study the prevalence, anatomical distribution, clinical correlates and outcomes of macrovascular disease (MVD) on duplex ultrasound (US) of the upper extremity in Systemic…
Abstract Number: 1388 • ACR Convergence 2021
Heterogeneity of Primary and Secondary Peristalsis in Systemic Sclerosis: A New Model of Scleroderma Esophagus
John Pandolfino¹, Harris Perlman¹, Monique Hinchcliff², Mary Carns³, John Pandolfino¹, John Pandolfino¹, Chase Correia¹ and John Pandolfino¹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Westport, CT, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Although esophageal dysmotility is common in systemic sclerosis (SSc), little is known regarding the pathophysiology of the motor abnormalities driving reflux severity and dysphagia.…
Abstract Number: 0497 • ACR Convergence 2021
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Victor Tapson¹, Steven Nathan², Reda Girgis³, James Runo⁴, Remzi Bag⁵, Arunabh Talwar⁶, Peter Smith⁷, Lisa Edwards⁷, Christine Park⁷ and Aaron Waxman⁸, ¹Cedars-Sinai, Los Angeles, CA, ²Inova Fairfax, Falls Church, VA, ³Michigan State University, Lansing, MI, ⁴University of Wisconsin, Madison, WI, ⁵University of Chicago, Chicago, IL, ⁶Hofstra Northwell School of Medicine, Hempstead, NY, ⁷United Therapeutics Corporation, Durham, NC, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease…
Abstract Number: 1434 • ACR Convergence 2021
Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?
Victor Farutin¹, Elma Kurtagic², Joel Pradines³, Ishan Capila³, Maureen Mayes⁴, Minghua Wu⁵, Anthony Manning³ and Shervin Assassi⁶, ¹Janssen R&D, LLC, Watertown, MA, ²Janssen R&D, LLC, Cambridge, ³Momenta Pharmaceuticals, Inc., Cambridge, MA, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁵University of Texas Health Science Center at Houston, Houston, TX, ⁶University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Discovery of biomarkers in systemic sclerosis (SSc) represents an unmet clinical need. Samples from prominently affected fibrotic end-organs such as lung and skin are…
Abstract Number: 0501 • ACR Convergence 2021
Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
Vishal Kakkar¹, Rebecca Ross², Ranjitha Karanth³, Sumit Lahiri⁴, Panji Mulipa¹, Pamela Hughes⁵, Brendan Clarke⁵, Clive Carter⁵, Mark Lobb⁵, Sinisa Savic⁶ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²LIRMM University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Transplant and Cellular Immunology, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a rare connective tissue disease with multi-systemic involvement, which at times requires the use of immunosuppressive medication. None of the…
Abstract Number: 1435 • ACR Convergence 2021
Identification of Distinct Fibroblast Populations in Systemic Sclerosis 3D Skin Tissues with Single Cell Omics
Noelle Kosarek¹, Heetaek Yang², Fred W. Kolling³, Tamar Abel⁴, Mengqi Huang⁵, Avi Smith⁶, Jonathan Garlick⁶, Patricia A. Pioli² and Michael L. Whitfield⁷, ¹Dartmouth Geisel School of Medicine, Hartford, VT, ²Geisel School of Medicine, Hanover, NH, ³Centers for Quantitative Biology, Hanover, ⁴Geisel School of Medicine, West Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Tufts University School of Dental Medicine, Boston, MA, ⁷Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by skin and internal organ fibrosis, vascular abnormalities, and autoantibody formation. Single cell genomics studies…
Abstract Number: 0542 • ACR Convergence 2021
Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis
Pamela Palisoc¹, Leah Vaikutis¹, Ellen Model¹, Morgan Omara¹, Dinesh Khanna¹, Eliza Pei-Suen Tsou¹ and Amr Sawalha², ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Glycoprotein nonmetastatic melanoma protein B (GPNMB) is widely expressed on stromal cells and immune cells. It is involved in various cell functions such as…
Abstract Number: 1643 • ACR Convergence 2021
Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
Xinyu Dou¹, David Kaelber² and Hulya Bukulmez¹, ¹MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ²The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH
Background/Purpose: COVID-19, as a member of the Coronavirus family, has been described to trigger host immune response via type I interferon (IFN) signaling pathways with…
Abstract Number: 0557 • ACR Convergence 2021
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Christopher Wasson¹, Eva Clavane², Rebecca Ross¹, Paul Meakin² and Francesco Del Galdo³, ¹LIRMM University of Leeds, Leeds, United Kingdom, ²LICAMM University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
Abstract Number: 1838 • ACR Convergence 2021
Further Construct Validation of the
Julia Spierings¹, Voon Ong² and Christopher Denton³, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University College London Medical School Royal Free Campus, London, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Evaluation of skin is central in clinical management of systemic sclerosis (SSc). Due to the COVID-19 pandemic remote consultations were widely implemented, which inevitably…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].